- Rachel Humphrey, a director at Pyxis Oncology, reported sales of 15,496 common shares in April 2025.
- The reported transactions were priced at USD 0.97 per share and USD 1.03 per share.
- Following the reported sales, Humphrey beneficially owned 81,309 common shares.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000905148-26-001434), on March 25, 2026, and is solely responsible for the information contained therein.